Table 2.
Clinical Outcomes of the Two Groups.
| non-SIRS | SIRS | ||
|---|---|---|---|
| N = 102 | N = 175 | p-value | |
| Z-score of the coronary artery at 1 week of the clinical course | |||
| RCA | 1.36 (1.79) | 1.54 (1.74) | 0.41 |
| LMCA | 1.96 (0.83) | 2.0 (1.07) | 0.74 |
| LAD | 1.25 (1.13) | 1.42 (1.45) | 0.31 |
| Z-score of the coronary artery at 1 month after treatment | |||
| RCA | 0.92 (1.84) | 1.09 (1.73) | 0.45 |
| LMCA | 1.63 (0.92) | 1.54 (1.0) | 0.45 |
| LAD | 0.92 (1.16) | 0.98 (1.48) | 0.71 |
| CAL at week 1 | 8 (7.8) | 31 (17.7) | 0.03 |
| CAL at month 1 | 4 (3.9) | 19 (10.9) | 0.03 |
| IVIG resistancea | 10 (10.5) | 12 (7.0) | 0.36 |
Data are expressed as n (%) or the mean (SD). The p-values were calculated using the Fisher's exact test.
RCA, right coronary artery; LMCA, left main coronary artery; LAD, left anterior descending artery; CAL, coronary artery lesion; and IVIG, intravenous immune globulin a Data on IVIG resistance were unavailable for seven patients with non-SIRS and three patients with SIRS.